Dogliotti, Irene
Jiménez, Cristina http://orcid.org/0000-0002-5543-5154
Varettoni, Marzia
Talaulikar, Dipti http://orcid.org/0000-0001-6766-8345
Bagratuni, Tina
Ferrante, Martina
Pérez, José
Drandi, Daniela
Puig, Noemí http://orcid.org/0000-0001-7535-3861
Gilestro, Milena
García-Álvarez, María
Owen, Roger
Jurczak, Wojciech http://orcid.org/0000-0003-1879-8084
Tedeschi, Alessandra
Leblond, Veronique
Kastritis, Efstathios http://orcid.org/0000-0001-8191-5832
Kersten, Marie José http://orcid.org/0000-0002-8904-3802
D’Sa, Shirley http://orcid.org/0000-0003-0840-3499
Kaščák, Michal
Willenbacher, Wolfgang
Roccaro, Aldo M. http://orcid.org/0000-0002-1872-5128
Poulain, Stephanie
Morel, Pierre http://orcid.org/0000-0002-0782-3144
Kyriakou, Charalampia
Fend, Falko http://orcid.org/0000-0002-5496-293X
Vos, Josephine M. I.
Dimopoulos, Meletios A. http://orcid.org/0000-0001-8990-3254
Buske, Christian http://orcid.org/0000-0002-9782-9012
Ferrero, Simone http://orcid.org/0000-0002-9711-1502
García-Sanz, Ramón
Funding for this research was provided by:
Roche
Janssen Pharmaceuticals
Gilead Foundation
Amgen
Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada
Celgene
Novartis Pharmaceuticals Corporation
Sanofi
Takeda Pharmaceuticals U.S.A.
AstraZeneca
European Hematology Association
Associazione Italiana per la Ricerca sul Cancro
AbbVie
Bayer
Celltrion Healthcare
Pfizer
Meso Scale Diagnostics
Janssen Biotech
Article History
Received: 15 September 2022
Revised: 7 November 2022
Accepted: 9 November 2022
First Online: 26 November 2022
Competing interests
: ID, CJ, MV, TB, MF, JP, DD, NP, MG, MG-A, RO, WJ, AT, VL, SP, CK, and FF declared no conflicts of interests related to this publication. DT has received honoraria from Amgen, Novartis, Roche, BeiGene, Janssen, Antengene, CSL and EUSA; has participated in advisory boards for Roche, Janssen, Antengene, CSL, BeiGene and EUSA; received research funding from Roche and Janssen. EK has received honoraria from Amgen, Genesis Pharma, Janssen, Takeda, GSK, Pfizer; has participated in advisory boards for Janssen, GSK; received research funding from Amgen, Janssen, and received travel and accommodations reimbursement from Janssen, GSK and Sanofi. MJK has received honoraria from Celgene/BMS, Roche, Kite/Gilead, Novartis, Miltenyi Biotec and Adicet Bio (all to institution) and research support from Kite/Gilead (to institution). SDS received honoraria from BeiGene, Janssen, and Sanofi; was a consultant/advisor for Janssen, BeiGene and Sanofi; received research funding from Janssen and received travel and accommodations reimbursement from Janssen, BeiGene and Sanofi. MK has received honoraria from Eusa Pharma, Janssen, Novartis, Roche, and Takeda; has participated in advisory boards for Eusa Pharma, Novartis, and Roche; received travel and accommodations reimbursement from Takeda. WW: Steering & Safety Committees AMGEN, Celgene, DSMM, Morphosys; Employee syndena (20%); Advisory Boards AMGEN, BMS—Celgene, EUSA Pharma, Gilead, GSK, Incyte, Janssen, Kite & Consultancies Novartis, Morphosys, Merck, Pfizer, Roche, Sandoz, Sanofi, Takeda; Lectures AMGEN, Abbvie, BMS—Celgene, EUSA Pharma, Fujimoto, Gilead, GSK, Incyte, Janssen, Myelom-und Lymphomselbsthilfe Österreich, Novartis, Pfizer, Roche, Sandoz, Sanofi, Takeda; Research Funding AMGEN, BMS, Celgene, Janssen, Novartis, Roche, Sanofi, Takeda oncotyrol; European Commission (FP7—OPTATIO) Bundesland Tirol Programm: “Translational research”. AMR: Research funding from AstraZeneca, European Hematology Association, Transcan2-ERANET/FRRB, Italian Association for Cancer Research (Fondazione AIRC). Honoraria from: Amgen, Celgene, Takeda, Janssen. PM has received honoraria from BeiGene, AstraZeneca and Janssen; was consultant/advisor for BeiGene, and Janssen. JMIV: travel and accommodations reimbursement from Celgene, has participated in an advisory board and as a consultant for Sanofi, and received research support (institutional) from BeiGene. MAD: honoraria from ABBVIE and Janssen; consultant/advisor for AstraZeneca, BeiGene, Janssen; travel and accommodation reimbursement from ABBVIE, AstraZeneca, BeiGene, Janssen. CB: Consultancy: Pfizer, AbbVie, Novartis, Janssen, BeiGene, Roche, Incyte, BMS, Celgene; Morphosys; Research funding: Roche, Janssen, AbbVie, Amgen, Bayer, Celltrion, Pfizer, MSD. SF: Janssen (Consultancy, Advisory board, Speakers honoraria, Research funding); EUSA Pharma (Consultancy, Advisory board, Speakers honoraria); Gilead, Morphosys (Research funding); Incyte, Clinigen (Advisory board); Servier, Gentili (Speakers honoraria). RG-S has received honoraria from Amgen, BeiGene, Janssen, and Takeda; was a consultant/advisor for Janssen; received research funding from Gilead; holds patents, royalties, or other intellectual property from BIOMED 2 Primers, and received travel and accommodations reimbursement from Janssen and Takeda. RG-S is the current president of the Spanish Society of Hematology and Hemotherapy (ExternalRef removed).